# R1 Clinical-Safety Review — appendiceal_mucinous_neoplasm

VERDICT: APPROVE

Confidence: 90. Goldens changed: no (intended: n/a — narrative KB content, no engine/rule change).
Adversarial-verify verdict file (.verdict.md): not present at the given path.

## 1. SAFETY — pass
No unsafe, misleading, or absolute directives found. Every therapeutic claim is
hedged and routes the decision to an MDT / specialist peritoneal-malignancy center:
- "usually curative", "usually prompt further imaging", "a multidisciplinary-team
  question rather than a fixed rule" — decision-support tone throughout.
- The one operative safety instruction is correct and protective: intact, non-ruptured
  en bloc appendicectomy and "a suspected mucocele should not be biopsied through the
  wall" (avoids iatrogenic peritoneal seeding). Consistent with standard teaching.
- No claim that could cause harm if followed. No over-reaching definitive diagnosis or
  "stop/never" med directive.

## 2. GROUNDING — pass
Claims align with DeVita/standard peritoneal-surface-oncology practice:
- CRS + perioperative intraperitoneal chemo (HIPEC or EPIC) as standard of care for
  PMP in specialist centers — correct.
- Lenient completeness-of-cytoreduction definition for low-grade mucinous disease
  (minute mucoid residual acceptable) vs strict CC-0 for colorectal/gastric — correct,
  genuine tumor-specific distinction.
- PCI ceiling used for MACA, none established for LAMN — correct.
- Signet-ring morphology worse prognosis with appendiceal as possible exception,
  neoadjuvant response as prognostic, salvage/repeat CRS at recurrence — all grounded
  and appropriately qualified.
- No RT role asserted (correctly, none in source). No fabricated regimen — systemic
  drug names are explicitly withheld pending NCCN sourcing.

## 3. DOSE-FREE — pass
No mg, mg/m2, AUC, or numbered schedule leaked. Grepped for numeric dosing; the only
figure present is a survival statistic (see Advisory), not a dose.

## 4. SCOPE — pass
Strongly scoped as decision-support: dedicated "Explicitly not asserted here" section,
repeated MDT/specialist-referral framing, and a closing source note flagging that NCCN
was not directly consulted and that systemic-regimen and surveillance details must be
verified at point of care. Exemplary hedging.

## Findings

Critical: none.

Important: none.

Advisory:
- The single quantitative claim — "historically reported around 85 percent survival at
  20 years in a landmark series" (line 9) — is the only hard number in the note. It is
  hedged as historical/landmark and is not a dose, so non-blocking, but the exact figure
  and time-point should be confirmed against the cited DeVita 12th ed. text before this
  ships, since long-term PMP survival figures vary by series and grade. Consider
  softening to "long-term survival" if the precise 85%/20-yr value cannot be pinned to
  the source.

No PHI touched and no AI-assisted engine logic changed, so no chaining to security- or
AI-reviewer is required for this content review.
